Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy

Clinical Infectious Diseases

Volumn 32, Issue 5, 2001, Pages 774-782

  Hanna, G J ^a   D'Aquila, R T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; ASSAY; DRUG CHOICE; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035282512     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319231     Document Type: Article

References (65)

1. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
2. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients
3. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy
4. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
5. Resistance of HIV-1 clinical isolates to efavirenz and other NNRTIs
6. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
7. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors
8. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
9. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing
10. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
11. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
12. Line probe assay for rapid detection of drug-sdected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
13. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples
14. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase
15. Comparative evaluation of three human immunodeficiency virus genotyping systems: The HIV-genotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay
16. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 dades and viral isolates with length polymorphisms
17. Antiretroviral drug resistance in HIV-1
18. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database
19. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
20. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
21. A blinded comparative analysis of two genotyping service laboratories: Full sequence analysis of HIV-1 protease and reverse transcriptase
22. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
23. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
24. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment
25. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
26. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients
27. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
28. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy
29. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure
30. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315
31. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy
32. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
33. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
34. Non-nucleoside reverse transcriprase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
35. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
36. The presence or absence of zidovudine in a nevirapine-containing antiretroviral regimen determines which of two nevirapine-limiting mutations occurs on virologic failure
37. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
38. Efavirenz response in NNRTI experienced patients: Results from the Sustiva Expanded Access Program
39. Can early failure with nevirapine (NVP)-based regimens be rescued replacing NVP by efavirenz?
40. Efficacy of an efavirenz (EFZ) and abacavir (ABC)-based salvage regimen according to previous use of nevirapine (NVP) and to baseline resistance patterns
41. Sequential use of non-nucleoside reverse transcriptase inhibitors in the clinical setting needs to be guided through genotypic and/or phenotypic analysis
42. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1
43. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
44. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
45. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
46. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
47. Impact of drug resistance mutations on virologic response to salvage therapy
48. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
49. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
50. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
51. Early virological failure in naïve human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO Trial) is not associated with mutations conferring vital resistance
52. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
53. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
54. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
55. The potential role of resistance decision support software with or without expert advice in a trial of HIV genotyping versus standard of care. The HAVANA Trial
56. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VILLA 3001) [abstract 84]
57. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients
58. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
59. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short-term virologic response
60. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
61. HIV-1 drug resistance in newly infected individuals
62. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
63. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
64. + T cell responses associated with control of viremia